DNA Blood Test Detects Cancer Resistance Using Inostics ...Manufacturing Digital (press release)Two studies published back-to-back in last week's Nature applied DNA blood testing using the BEAMing technology to detect drug resistance mediated by KRAS...
Cetuximab, brivanib failed to extend OS in metastatic colorectal carcinoma— Despite improvements in PFS and objective response, the combination of cetuximab and brivanib alaninate did not improve survival for patients with...
This week’s New England Journal of Medicine (NEJM) contained a fascinating article on how a specific gene mutation known as Transcription factor AP-2 epsilon, TFAP2E–DKK4, appears to be responsible for inducing at least some of the resistance to...
"In this study, PDTT xenograft models of colon carcinoma with lymphatic and hepatic metastasis have been successfully established. They provide appropriate models for testing of novel molecularly targeted agents..."
STOCKHOLM – The experimental cytotoxic agent TAS-102 significantly reduced the risk of death in a placebo-controlled phase II trial of patients with metastatic colorectal cancer refractory to current treatments.
STOCKHOLM -- Patients who've undergone treatment for metastatic colorectal cancer had statistically significant and clinically meaningful improvement in survival when also given a multitargeted angi...
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. (Early detection #epigenetic biomarker for #coloncancer.
Food and Drug Administration will review therascreen® KRAS RGQ PCR Kit for use with Erbitux® (cetuximab), a metastatic colorectal cancer therapyPMA follows a recent submission for use with another EGFR inhibitor drug, also in patients with metastatic colorectal cancerQIAGEN achieves milestones in Personalized Healthcare with innovative companion diagnostics; FDA decisions expected in 2012
Background: Macrophage inhibitory cytokine-1 (MIC-1/GDF15) mediates nonsteroidal anti-inflammatory drug (NSAID) protection from colonic polyps in mice and is linked to the development of colorectal carcinoma in humans.
Study Shows Epigenomics Biomarker Predicts Drug Resistance In Colorectal CancerNASDAQPK) Thursday said a study published in the January edition of The New England Journal of Medicine demonstrates the potential of TFAP2E and other biomarkers identified...
"Although the vast majority of melanoma patients with BRAF-mutant tumors respond to BRAF inhibitors, the same is not true for colon cancer patients with the mutation. One study reported that just 5% of colon cancer patients with BRAF-mutant tumors responded to the BRAF inhibitor vemurafenib. Now, data from a functional genomics screen may explain that paradox, researchers reported here at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.
Remarkably, the data also suggest that combining an EGFR inhibitor with a BRAF inhibitor may dramatically improve responses in patients with BRAF-mutant colon cancer..."
"MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, announced today that its licensing partner Exact Sciences Corp. (Nasdaq: EXAS) has initiated a large pivotal trial for Cologuard™, its non-invasive, stool-based DNA colon cancer screening test. Exact confirmed that it is using an MDxHealth methylation biomarker together with MDxHealth's methylation specific PCR (MSP [FREE Stock Trend Analysis]) platform in Cologuard.
Exact's multi-center DeeP-C study (Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer) will generate data to support its planned PMA submission to the U.S. Food and Drug Administration (FDA) in 2012. The company began enrolling patients in the study on June 30, 2011. It is planning to qualify approximately 60 sites in the United States and Canada for the study. Those sites are expected to enroll more than 10,000 patients between the ages of 50 and 84 who are at average risk for colorectal cancer."
The addition of aflibercept (VEGF Trap, Zaltrap) to standard chemotherapy was associated with about a six-week improvement in overall survival and a two-month increase in progression-free survival compared with ...
Sharing your scoops to your social media accounts is a must to distribute your curated content. Not only will it drive traffic and leads through your content, but it will help show your expertise with your followers.
How to integrate my topics' content to my website?
Integrating your curated content to your website or blog will allow you to increase your website visitors’ engagement, boost SEO and acquire new visitors. By redirecting your social media traffic to your website, Scoop.it will also help you generate more qualified traffic and leads from your curation work.
Distributing your curated content through a newsletter is a great way to nurture and engage your email subscribers will developing your traffic and visibility.
Creating engaging newsletters with your curated content is really easy.